|
Title
|
|
|
|
Quality assurance of radiation therapy after breast-conserving surgery among patients in the BOOG 2013-08 trial
| |
|
Author
|
|
|
|
| |
|
Institution/Organisation
|
|
|
|
BOOG 2013-08 Group
| |
|
Abstract
|
|
|
|
| Background and purpose: In the BOOG 2013-08 trial (NCT02271828), cT1-2N0 breast cancer patients were randomized between breast conserving surgery with or without sentinel lymph node biopsy (SLNB) followed by whole breast radiotherapy (WBRT). While awaiting primary endpoint results (axillary recurrence rate), this study aims to perform a quality assurance analysis on protocol adherence and (incidental) axillary radiation therapy (RT) dose. Materials and methods: Patients were enrolled between 2015 and 2022. Data on prescribed RT and (in 25% of included patients) planning target volumes (PTV) parameters were recorded for axillary levels I -IV and compared between treatment arms. Multivariable linear regression analysis was performed to determine prognostic variables for incidental axillary RT dose. Results: 1,439/1,461 included patients (98.5%) were treated according to protocol and 87 patients (5.9%) received regional RT (SLNB 10.9%, no-SLNB 1.5 %). In 326 patients included in the subgroup analysis, the mean incidental PTV dose at axilla level I was 59.5% of the prescribed breast RT dose. In 5 patients (1.5%) the mean PTV dose at level I was >= 95% of the prescribed breast dose. No statistically or clinically significant differences regarding incidental axillary RT dose were found between treatment arms. Tumour bed boost (yes/no) was associated with a higher incidental mean dose in level I (R2 = 0.035, F(6, 263) = 1.532, p 0.168). Conclusion: The results indicate that RT-protocol adherence was high, and that incidental axillary RT dose was low in the BOOG 2013-08 trial. Potential differences between treatmentarms regarding the primary endpoint can thus not be attributed to different axillary radiation doses. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Radiotherapy and oncology. - Amsterdam
| |
|
Publication
|
|
|
|
Amsterdam
:
2024
| |
|
ISSN
|
|
|
|
0167-8140
| |
|
DOI
|
|
|
|
10.1016/J.RADONC.2023.110069
| |
|
Volume/pages
|
|
|
|
191
(2024)
, p. 1-9
| |
|
Article Reference
|
|
|
|
110069
| |
|
ISI
|
|
|
|
001154825200001
| |
|
Pubmed ID
|
|
|
|
38141879
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (open access)
|
|
|
|
| |
|